4.8 Article

Natural Killer Cells Eradicate Galectin-1-Deficient Glioma in the Absence of Adaptive Immunity

Journal

CANCER RESEARCH
Volume 74, Issue 18, Pages 5079-5090

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-1203

Keywords

-

Categories

Funding

  1. NIH/National Institute of Neurological Disorders & Stroke (NIH/NINDS) [1RO1-NS 054193, 1RO1-NS 061107, 1RO1-NS082311]
  2. [1UO1-NS052465]
  3. [1RO1-NS 057711]
  4. [1RO1-NS074387]

Ask authors/readers for more resources

Natural killer (NK) cells safeguard against early tumor formation by destroying transformed target cells in a process referred to as NK immune surveillance. However, the immune escape mechanisms used by malignant brain tumors to subvert this innate type of immune surveillance remain unclear. Here we show that malignant glioma cells suppress NK immune surveillance by overexpressing the beta-galactoside-binding lectin galectin-1. Conversely, galectin-1-deficient glioma cells could be eradicated by host NK cells before the initiation of an antitumor T-cell response. In vitro experiments demonstrated that galectin-1-deficient GL26-Cit glioma cells are similar to 3-fold more sensitive to NK-mediated tumor lysis than galectin-1-expressing cells. Our findings suggest that galectin-1 suppression in human glioma could improve patient survival by restoring NK immune surveillance that can eradicate glioma cells. (C) 2014 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available